Shanghai Shen Lian Biomedical Corp - Asset Resilience Ratio
Shanghai Shen Lian Biomedical Corp (688098) has an Asset Resilience Ratio of 0.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Shen Lian Biomedical Corp (688098) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Shanghai Shen Lian Biomedical Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Shanghai Shen Lian Biomedical Corp.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Shen Lian Biomedical Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Shanghai Shen Lian Biomedical Corp for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥10.52 Million | 0.69% |
| Total Liquid Assets | CN¥10.52 Million | 0.69% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Shen Lian Biomedical Corp maintains only 0.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Shen Lian Biomedical Corp Industry Peers by Asset Resilience Ratio
Compare Shanghai Shen Lian Biomedical Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Shanghai Shen Lian Biomedical Corp (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Shanghai Shen Lian Biomedical Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.13% | CN¥32.82 Million ≈ $4.80 Million |
CN¥1.54 Billion ≈ $225.70 Million |
-0.69pp |
| 2024-12-31 | 2.82% | CN¥43.81 Million ≈ $6.41 Million |
CN¥1.55 Billion ≈ $227.42 Million |
-7.37pp |
| 2023-12-31 | 10.19% | CN¥162.38 Million ≈ $23.76 Million |
CN¥1.59 Billion ≈ $233.25 Million |
-8.82pp |
| 2022-12-31 | 19.01% | CN¥305.12 Million ≈ $44.65 Million |
CN¥1.61 Billion ≈ $234.87 Million |
-7.52pp |
| 2021-12-31 | 26.53% | CN¥424.08 Million ≈ $62.06 Million |
CN¥1.60 Billion ≈ $233.91 Million |
-4.67pp |
| 2020-12-31 | 31.20% | CN¥472.45 Million ≈ $69.13 Million |
CN¥1.51 Billion ≈ $221.61 Million |
-- |
About Shanghai Shen Lian Biomedical Corp
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.